{"pmid":32461288,"title":"Patients with Common Cold Coronaviruses Tested Negative for IgG Antibody to SARS-CoV-2.","text":["Patients with Common Cold Coronaviruses Tested Negative for IgG Antibody to SARS-CoV-2.","The need for accurate antibody testing in patients following symptomatic or asymptomatic infections with SARS-CoV-2 is well documented.....","J Clin Microbiol","Brecher, Stephen M","Dryjowicz-Burek, Jonathan","Yu, Hongbo","Campbell, Sheldon","Ratcliffe, Nora","Gupta, Kalpana","32461288"],"abstract":["The need for accurate antibody testing in patients following symptomatic or asymptomatic infections with SARS-CoV-2 is well documented....."],"journal":"J Clin Microbiol","authors":["Brecher, Stephen M","Dryjowicz-Burek, Jonathan","Yu, Hongbo","Campbell, Sheldon","Ratcliffe, Nora","Gupta, Kalpana"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461288","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1128/JCM.01029-20","topics":["Diagnosis"],"weight":1,"_version_":1668079521412153344,"score":9.490897,"similar":[{"pmid":32104917,"title":"Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis.","text":["Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis.","The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (severe acute respiratory syndrome coronavirus [SARS-Cov-2]) nucleic acid real-time polymerase chain reaction (PCR) test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false-negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify a large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay that can detect immunoglobulin M (IgM) and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at eight different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories.","J Med Virol","Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng","32104917"],"abstract":["The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (severe acute respiratory syndrome coronavirus [SARS-Cov-2]) nucleic acid real-time polymerase chain reaction (PCR) test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false-negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify a large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay that can detect immunoglobulin M (IgM) and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at eight different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories."],"journal":"J Med Virol","authors":["Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32104917","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25727","keywords":["covid-19","sars-cov-2 virus infection","fingerstick blood","lateral flow immunoassay","point-of-care testing","rapid igm-igg combined test"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492879503361,"score":88.87766},{"pmid":32330303,"title":"Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","text":["Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang","32330303"],"abstract":["Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330303","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25930","keywords":["covid-19","igg","igm","sars-cov-2","diagnosis"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494560370688,"score":84.18042},{"pmid":32387968,"title":"Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","text":["Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19.","J Clin Virol","Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya","32387968"],"abstract":["BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19."],"journal":"J Clin Virol","authors":["Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387968","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104393","keywords":["covid-19","chest ct scan","immunochromatographic assay","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892589588482,"score":74.57585},{"pmid":32330291,"title":"Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.","text":["Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.","BACKGROUND: A pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID-19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID-19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play. METHODS: Sixty-one COVID-19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti-SARS CoV-2 antibodies IgM and IgG. All COVID-19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab RT-PCR result. RESULTS: The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The ROC performance curves showed area under the curve (AUC) values of 0.918 and 0.980 for anti-SARS CoV-2 antibodies IgM and IgG, respectively. CONCLUSIONS: iFlash1800 CLIA analyzer has shown highly accurate results for the anti-SARS-CoV-2 antibodies profile and can be considered an excellent tool for COVID-19 diagnostics. This article is protected by copyright. All rights reserved.","J Med Virol","Infantino, M","Grossi, V","Lari, B","Bambi, R","Perri, A","Manneschi, M","Terenzi, G","Liotti, I","Ciotta, G","Taddei, C","Benucci, M","Casprini, P","Veneziani, F","Fabbri, S","Pompetti, A","Manfredi, M","32330291"],"abstract":["BACKGROUND: A pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID-19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID-19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play. METHODS: Sixty-one COVID-19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti-SARS CoV-2 antibodies IgM and IgG. All COVID-19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab RT-PCR result. RESULTS: The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The ROC performance curves showed area under the curve (AUC) values of 0.918 and 0.980 for anti-SARS CoV-2 antibodies IgM and IgG, respectively. CONCLUSIONS: iFlash1800 CLIA analyzer has shown highly accurate results for the anti-SARS-CoV-2 antibodies profile and can be considered an excellent tool for COVID-19 diagnostics. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Infantino, M","Grossi, V","Lari, B","Bambi, R","Perri, A","Manneschi, M","Terenzi, G","Liotti, I","Ciotta, G","Taddei, C","Benucci, M","Casprini, P","Veneziani, F","Fabbri, S","Pompetti, A","Manfredi, M"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330291","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25932","keywords":["coronavirus","humoral immunity","immune responses","sars coronavirus","virus classification"],"locations":["San Giovanni","Florence","Italy","analyzer","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494570856448,"score":71.00037},{"pmid":32473953,"title":"Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients.","text":["Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients.","OBJECTIVES: To evaluate the diagnostic performance of 7 rapid IgG/IgM tests and the Euroimmun IgA/IgG ELISA for antibodies against SARS-CoV-2 in COVID-19 patients. METHODS: Specificity was evaluated in 103 samples collected before January 2020. Sensitivity and time to seropositivity was evaluated in samples from 94 patients with COVID-19 confirmed with PCR on nasopharyngeal swab. RESULTS: Specificity [confidence interval] of lateral flow assays (LFA) was >/= 91.3% [84.0-95.5] for IgM, >/= 90.3% [82.9-94.8] for IgG, and >/= 85.4% [77.2-91.1] for the combination IgM OR IgG. Specificity of the ELISA was 96.1% [90.1-98.8] for IgG and only 73.8% [64.5-81.4] for IgA. Sensitivity 14-25 days after onset of symptoms was >/= 92.1% [78.5-98.0] to 100% [95.7-100] for IgG LFA compared to 89.5% [75.3-96.4] for IgG ELISA. Positivity of IgM OR IgG for LFA resulted in a decrease in specificity compared to IgG alone without a gain in diagnostic performance except for VivaDiag. The results for IgM varied significantly between the LFA with an average overall agreement of only 70% compared to 89% for IgG. The average dynamic trend to seropositivity for IgM was not shorter than for IgG. At time of admission to the hospital, the sensitivity of LFA was <60%. CONCLUSIONS: Sensitivity for the detection IgG antibodies 14-25 days after onset of symptoms was >/= 92.1% for all 7 LFA compared to 89.5% for the IgG ELISA. The results for IgM varied significantly and including IgM antibodies in addition to IgG for the interpretation of LFA did not improve the diagnostic performance.","Clin Microbiol Infect","Van Elslande, Jan","Houben, Els","Depypere, Melissa","Brackenier, Anouk","Desmet, Stefanie","Andre, Emmanuel","Van Ranst, Marc","Lagrou, Katrien","Vermeersch, Pieter","32473953"],"abstract":["OBJECTIVES: To evaluate the diagnostic performance of 7 rapid IgG/IgM tests and the Euroimmun IgA/IgG ELISA for antibodies against SARS-CoV-2 in COVID-19 patients. METHODS: Specificity was evaluated in 103 samples collected before January 2020. Sensitivity and time to seropositivity was evaluated in samples from 94 patients with COVID-19 confirmed with PCR on nasopharyngeal swab. RESULTS: Specificity [confidence interval] of lateral flow assays (LFA) was >/= 91.3% [84.0-95.5] for IgM, >/= 90.3% [82.9-94.8] for IgG, and >/= 85.4% [77.2-91.1] for the combination IgM OR IgG. Specificity of the ELISA was 96.1% [90.1-98.8] for IgG and only 73.8% [64.5-81.4] for IgA. Sensitivity 14-25 days after onset of symptoms was >/= 92.1% [78.5-98.0] to 100% [95.7-100] for IgG LFA compared to 89.5% [75.3-96.4] for IgG ELISA. Positivity of IgM OR IgG for LFA resulted in a decrease in specificity compared to IgG alone without a gain in diagnostic performance except for VivaDiag. The results for IgM varied significantly between the LFA with an average overall agreement of only 70% compared to 89% for IgG. The average dynamic trend to seropositivity for IgM was not shorter than for IgG. At time of admission to the hospital, the sensitivity of LFA was <60%. CONCLUSIONS: Sensitivity for the detection IgG antibodies 14-25 days after onset of symptoms was >/= 92.1% for all 7 LFA compared to 89.5% for the IgG ELISA. The results for IgM varied significantly and including IgM antibodies in addition to IgG for the interpretation of LFA did not improve the diagnostic performance."],"journal":"Clin Microbiol Infect","authors":["Van Elslande, Jan","Houben, Els","Depypere, Melissa","Brackenier, Anouk","Desmet, Stefanie","Andre, Emmanuel","Van Ranst, Marc","Lagrou, Katrien","Vermeersch, Pieter"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32473953","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.cmi.2020.05.023","keywords":["covid-19","diagnosis","elisa","immunoassay","lateral flow assay","point-of-care testing","sars-cov-2","sensitivity and specificity","seroconversion"],"topics":["Diagnosis"],"weight":1,"_version_":1668341932710952962,"score":68.46968}]}